Dr. Manish Wadhwa M.D. serves as Chief Medical Officer of the Company. Dr. Wadhwa received his undergraduate training at Penn State University and his M.D. degree from Thomas Jefferson University in Philadelphia, PA, where he trained in internal medicine and general cardiology. He completed his cardiology training with two years of advanced fellowship in cardiac electrophysiology at the University of California San Diego. He has served on the physician advisory boards of Medtronic, Boston Scientific, Biotronik, St. Jude Medical and Sanofi-Aventis, and is a fellow of the Heart Rhythm Society. Dr. Wadhwa has authored numerous medical papers, lectures on clinical issues in cardiac electrophysiology and continues to be involved with post-market evaluations of commercially available implanted device leads and generators.
Manish's mailing address filed with the SEC is 1000 CEDAR HOLLOW ROAD, , MALVERN, PA, 19355.
Over the last 11 years, insiders at HeartBeam Inc have traded over $23,124,978 worth of HeartBeam Inc stock and bought 31,500 units worth $221,145 . The most active insiders traders include Joseph H Capper, Heather C Getz, and Willem Elfrink. On average, HeartBeam Inc executives and independent directors trade stock every 32 days with the average trade being worth of $55,046. The most recent stock trade was executed by Urioste George De on 6 September 2024, trading 1,674 units of BEAT stock currently worth $3,917.
heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.
HeartBeam Inc executives and other stock owners filed with the SEC include: